首页 > 最新文献

Tzu Chi Medical Journal最新文献

英文 中文
Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors. 天然植物化学物质作为小分子蛋白转化酶枯草酶/kexin 9 型抑制剂。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-05 eCollection Date: 2024-10-01 DOI: 10.4103/tcmj.tcmj_46_24
Je-Wen Liou, Pei-Yi Chen, Wan-Yun Gao, Jui-Hung Yen

A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases. Increasing the expression level or inducing the activity of LDLR in hepatocytes can effectively control hypercholesterolemia. Proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, primarily produced in the liver, promotes the degradation of LDLR. Inhibiting the expression and/or function of PCSK9 can increase the levels of LDLR on the surface of hepatocytes and promote LDL-C clearance from the plasma. Thus, targeting PCSK9 represents a new strategy for developing preventive and therapeutic interventions for hypercholesterolemia. Currently, monoclonal antibodies are used as PCSK9 inhibitors in clinical practice. However, the need for oral and affordable anti-PCSK9 medications limits the perspective of choosing PCSK9 inhibitors for clinical usage. Emerging research reports have demonstrated that natural phytochemicals have efficacy in maintaining cholesterol stability and regulating lipid metabolism. Developing novel natural phytochemical PCSK9 inhibitors can serve as a starting point for developing small-molecule drugs to reduce plasma LDL-C levels in patients. In this review, we summarize the current literature on the critical role of PCSK9 in controlling LDLR degradation and hypercholesterolemia, and we discuss the results of studies attempting to develop PCSK9 inhibitors, with an emphasis on the inhibitory effects of natural phytochemicals on PCSK9. Furthermore, we provide insight into the mechanisms of action by which the reported phytochemicals exert their potential PCSK9 inhibitory effects against hypercholesterolemia.

低密度脂蛋白受体(LDLR)水平下降会导致低密度脂蛋白胆固醇(LDL-C)在血液中积累,从而引起高胆固醇血症和动脉粥样硬化性心血管疾病。提高肝细胞中 LDLR 的表达水平或诱导其活性可有效控制高胆固醇血症。Proprotein convertase subtilisin/kexin type 9(PCSK9)蛋白主要产生于肝脏,可促进 LDLR 的降解。抑制 PCSK9 的表达和/或功能可提高肝细胞表面的 LDLR 水平,促进血浆中 LDL-C 的清除。因此,靶向 PCSK9 是开发高胆固醇血症预防和治疗干预措施的新策略。目前,临床上使用单克隆抗体作为 PCSK9 抑制剂。然而,由于需要口服且价格低廉的抗 PCSK9 药物,限制了临床使用 PCSK9 抑制剂的选择范围。新的研究报告表明,天然植物化学物质具有维持胆固醇稳定性和调节脂质代谢的功效。开发新型天然植物化学 PCSK9 抑制剂可作为开发小分子药物的起点,以降低患者的血浆 LDL-C 水平。在这篇综述中,我们总结了目前有关 PCSK9 在控制 LDLR 降解和高胆固醇血症中的关键作用的文献,并讨论了试图开发 PCSK9 抑制剂的研究结果,重点是天然植物化学物质对 PCSK9 的抑制作用。此外,我们还深入探讨了所报道的植物化学物质对高胆固醇血症产生潜在 PCSK9 抑制作用的作用机制。
{"title":"Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors.","authors":"Je-Wen Liou, Pei-Yi Chen, Wan-Yun Gao, Jui-Hung Yen","doi":"10.4103/tcmj.tcmj_46_24","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_46_24","url":null,"abstract":"<p><p>A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases. Increasing the expression level or inducing the activity of LDLR in hepatocytes can effectively control hypercholesterolemia. Proprotein convertase subtilisin/kexin type 9 (PCSK9) protein, primarily produced in the liver, promotes the degradation of LDLR. Inhibiting the expression and/or function of PCSK9 can increase the levels of LDLR on the surface of hepatocytes and promote LDL-C clearance from the plasma. Thus, targeting PCSK9 represents a new strategy for developing preventive and therapeutic interventions for hypercholesterolemia. Currently, monoclonal antibodies are used as PCSK9 inhibitors in clinical practice. However, the need for oral and affordable anti-PCSK9 medications limits the perspective of choosing PCSK9 inhibitors for clinical usage. Emerging research reports have demonstrated that natural phytochemicals have efficacy in maintaining cholesterol stability and regulating lipid metabolism. Developing novel natural phytochemical PCSK9 inhibitors can serve as a starting point for developing small-molecule drugs to reduce plasma LDL-C levels in patients. In this review, we summarize the current literature on the critical role of PCSK9 in controlling LDLR degradation and hypercholesterolemia, and we discuss the results of studies attempting to develop PCSK9 inhibitors, with an emphasis on the inhibitory effects of natural phytochemicals on PCSK9. Furthermore, we provide insight into the mechanisms of action by which the reported phytochemicals exert their potential PCSK9 inhibitory effects against hypercholesterolemia.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 4","pages":"360-369"},"PeriodicalIF":1.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unraveling the interplay between inflammation and stem cell mobilization or homing: Implications for tissue repair and therapeutics. 揭示炎症与干细胞动员或归巢之间的相互作用:对组织修复和治疗的影响。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-05 eCollection Date: 2024-10-01 DOI: 10.4103/tcmj.tcmj_100_24
Hsin-Hou Chang, Yu-Shan Liou, Der-Shan Sun

Inflammation and stem cell mobilization or homing play pivotal roles in tissue repair and regeneration. This review explores their intricate interplay, elucidating their collaborative role in maintaining tissue homeostasis and responding to injury or disease. While examining the fundamentals of stem cells, we detail the mechanisms underlying inflammation, including immune cell recruitment and inflammatory mediator release, highlighting their self-renewal and differentiation capabilities. Central to our exploration is the modulation of hematopoietic stem cell behavior by inflammatory cues, driving their mobilization from the bone marrow niche into circulation. Key cytokines, chemokines, growth factors, and autophagy, an intracellular catabolic mechanism involved in this process, are discussed alongside their clinical relevance. Furthermore, mesenchymal stem cell homing in response to inflammation contributes to tissue repair processes. In addition, we discuss stem cell resilience in the face of inflammatory challenges. Moreover, we examine the reciprocal influence of stem cells on the inflammatory milieu, shaping immune responses and tissue repair. We underscore the potential of targeting inflammation-induced stem cell mobilization for regenerative therapies through extensive literature analysis and clinical insights. By unraveling the complex interplay between inflammation and stem cells, this review advances our understanding of tissue repair mechanisms and offers promising avenues for clinical translation in regenerative medicine.

炎症和干细胞动员或归巢在组织修复和再生中发挥着关键作用。这篇综述探讨了它们之间错综复杂的相互作用,阐明了它们在维持组织稳态和应对损伤或疾病方面的协同作用。在研究干细胞基本原理的同时,我们详细介绍了炎症的内在机制,包括免疫细胞招募和炎症介质释放,突出了干细胞的自我更新和分化能力。我们探索的核心是炎症线索对造血干细胞行为的调控,推动其从骨髓龛动员进入血液循环。我们讨论了关键的细胞因子、趋化因子、生长因子和自噬(参与这一过程的细胞内分解代谢机制),以及它们的临床意义。此外,间充质干细胞因炎症而归巢也有助于组织修复过程。此外,我们还讨论了干细胞面对炎症挑战时的恢复能力。此外,我们研究了干细胞对炎症环境的相互影响,从而形成免疫反应和组织修复。我们通过广泛的文献分析和临床见解,强调了针对炎症诱导的干细胞动员进行再生治疗的潜力。通过揭示炎症与干细胞之间复杂的相互作用,这篇综述加深了我们对组织修复机制的理解,并为再生医学的临床转化提供了前景广阔的途径。
{"title":"Unraveling the interplay between inflammation and stem cell mobilization or homing: Implications for tissue repair and therapeutics.","authors":"Hsin-Hou Chang, Yu-Shan Liou, Der-Shan Sun","doi":"10.4103/tcmj.tcmj_100_24","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_100_24","url":null,"abstract":"<p><p>Inflammation and stem cell mobilization or homing play pivotal roles in tissue repair and regeneration. This review explores their intricate interplay, elucidating their collaborative role in maintaining tissue homeostasis and responding to injury or disease. While examining the fundamentals of stem cells, we detail the mechanisms underlying inflammation, including immune cell recruitment and inflammatory mediator release, highlighting their self-renewal and differentiation capabilities. Central to our exploration is the modulation of hematopoietic stem cell behavior by inflammatory cues, driving their mobilization from the bone marrow niche into circulation. Key cytokines, chemokines, growth factors, and autophagy, an intracellular catabolic mechanism involved in this process, are discussed alongside their clinical relevance. Furthermore, mesenchymal stem cell homing in response to inflammation contributes to tissue repair processes. In addition, we discuss stem cell resilience in the face of inflammatory challenges. Moreover, we examine the reciprocal influence of stem cells on the inflammatory milieu, shaping immune responses and tissue repair. We underscore the potential of targeting inflammation-induced stem cell mobilization for regenerative therapies through extensive literature analysis and clinical insights. By unraveling the complex interplay between inflammation and stem cells, this review advances our understanding of tissue repair mechanisms and offers promising avenues for clinical translation in regenerative medicine.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 4","pages":"349-359"},"PeriodicalIF":1.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic modification in radiotherapy and immunotherapy for cancers. 癌症放疗和免疫疗法中的表观遗传修饰。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-05 eCollection Date: 2024-10-01 DOI: 10.4103/tcmj.tcmj_3_24
Shih-Kai Hung, Moon-Sing Lee, Wen-Yen Chiou, Dai-Wei Liu, Chih-Chia Yu, Liang-Cheng Chen, Ru-Inn Lin, Chia-Hui Chew, Feng-Chun Hsu, Hsuan-Ju Yang, Michael W Y Chan, Hon-Yi Lin

Radiotherapy (RT) is one of the primary treatment modalities in managing cancer patients. Recently, combined RT and immunotherapy (IT) (i.e., radio-IT [RIT]) have been aggressively investigated in managing cancer patients. However, several issues in conducting RIT are challenging, such as incorporating advanced irradiation techniques, predictive/prognostic biomarkers, and other treatment modalities. Several clinical efforts and novel biomarkers have been introduced and developed to solve these challenges. For example, stereotactic radiosurgery/stereotactic radiotherapy, stereotactic body radiotherapy/stereotactic ablative body radiotherapy, and FLASH-RT have been applied for delivering precise irradiation to lung and liver tumors in conjunction with IT. Besides, several novel IT agents and incorporations of other therapies, such as targeted and thermal therapies, have been further investigated. The present study reviewed the emerging challenges of RIT in modern oncology. We also evaluated clinical practice, bench research, and multimodality treatments. In addition to several clinically applicable biomarkers, we emphasize the roles of advanced irradiation techniques and epigenetic modification as predictive/prognostic biomarkers and potential therapeutic targets. For example, 6(m) A-based epigenetic agents demonstrate the potential to enhance the treatment effects of RIT. However, further prospective randomized trials should be conducted to confirm their roles.

放疗(RT)是治疗癌症患者的主要方法之一。最近,人们积极研究将 RT 和免疫疗法(IT)相结合(即放射-IT [RIT])来治疗癌症患者。然而,开展 RIT 有几个具有挑战性的问题,如结合先进的照射技术、预测/诊断生物标志物和其他治疗模式。为了解决这些难题,已经引入和开发了一些临床工作和新型生物标志物。例如,立体定向放射手术/立体定向放射治疗、立体定向体放射治疗/立体定向消融体放射治疗和FLASH-RT已被应用于结合IT对肺部和肝部肿瘤进行精确照射。此外,一些新型 IT 药剂和其他疗法(如靶向疗法和热疗法)也得到了进一步研究。本研究回顾了 RIT 在现代肿瘤学中面临的新挑战。我们还评估了临床实践、基础研究和多模式疗法。除了几种临床适用的生物标志物外,我们还强调了先进辐照技术和表观遗传修饰作为预测/诊断生物标志物和潜在治疗靶点的作用。例如,以 6(m) A 为基础的表观遗传制剂显示出增强 RIT 治疗效果的潜力。不过,应进一步开展前瞻性随机试验以确认其作用。
{"title":"Epigenetic modification in radiotherapy and immunotherapy for cancers.","authors":"Shih-Kai Hung, Moon-Sing Lee, Wen-Yen Chiou, Dai-Wei Liu, Chih-Chia Yu, Liang-Cheng Chen, Ru-Inn Lin, Chia-Hui Chew, Feng-Chun Hsu, Hsuan-Ju Yang, Michael W Y Chan, Hon-Yi Lin","doi":"10.4103/tcmj.tcmj_3_24","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_3_24","url":null,"abstract":"<p><p>Radiotherapy (RT) is one of the primary treatment modalities in managing cancer patients. Recently, combined RT and immunotherapy (IT) (i.e., radio-IT [RIT]) have been aggressively investigated in managing cancer patients. However, several issues in conducting RIT are challenging, such as incorporating advanced irradiation techniques, predictive/prognostic biomarkers, and other treatment modalities. Several clinical efforts and novel biomarkers have been introduced and developed to solve these challenges. For example, stereotactic radiosurgery/stereotactic radiotherapy, stereotactic body radiotherapy/stereotactic ablative body radiotherapy, and FLASH-RT have been applied for delivering precise irradiation to lung and liver tumors in conjunction with IT. Besides, several novel IT agents and incorporations of other therapies, such as targeted and thermal therapies, have been further investigated. The present study reviewed the emerging challenges of RIT in modern oncology. We also evaluated clinical practice, bench research, and multimodality treatments. In addition to several clinically applicable biomarkers, we emphasize the roles of advanced irradiation techniques and epigenetic modification as predictive/prognostic biomarkers and potential therapeutic targets. For example, 6(m) A-based epigenetic agents demonstrate the potential to enhance the treatment effects of RIT. However, further prospective randomized trials should be conducted to confirm their roles.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 4","pages":"396-406"},"PeriodicalIF":1.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The obesity paradox exists in Asia: A systematic review and meta-analysis of body mass index effects on clinical outcomes following percutaneous coronary intervention in Asia. 亚洲存在肥胖悖论:亚洲经皮冠状动脉介入治疗后体重指数对临床结果影响的系统回顾和荟萃分析。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-09-05 eCollection Date: 2024-10-01 DOI: 10.4103/tcmj.tcmj_317_23
Andrianto, Chabib Fachry Albab, Nandha Pratama Mahardika

Cardiovascular diseases (CVDs) are major contributors to illness and death globally. Body mass index (BMI) is a well-established prognostic factor on cardiovascular risk outcome. Numerous investigations have provided evidence for the existence of the obesity paradox after percutaneous coronary intervention (PCI). However, the association between BMI and the results following PCI has not been extensively investigated in Asian populations. The research aims to fill the current void in understanding by investigating the association between BMI and clinical consequences following PCI, with a particular focus on Asian individuals. A systematic search was conducted through PubMed, ScienceDirect, and Cochrane Library to identify studies examining the effect of BMI on clinical outcome after PCI in Asia. R Studio 4.3.2 software was used to carry out the analysis of the data. A total of 182,110 patients who had gone through PCI were found in the 5 included cohorts. A meta-analysis conducted on the subjects revealed that patients who were overweight (odds ratio [OR] = 0.60, 95% confidence interval [CI] [0.57, 0.63], P < 0.0001) had a lower risk of all-cause mortality compared to individuals with a healthy weight and patients with obesity (OR = 0.65, 95% CI [0.41, 1.05], P = 0.006) had a lower risk of all-cause mortality than healthy weight individuals. The study also found that overweight patients (OR = 0.60, 95% CI [0.39, 0.91], P = 0.02) had a lower risk of cardiac mortality. In addition, obese patients (OR = 0.41, 95% CI [0.19, 0.88], P = 0.02) had a lower risk of noncardiac mortality. However, the study found that there were no differences in major adverse cardiovascular event, myocardial infarction, and bleeding between all patient groups. This meta-analysis supports the presence of an obesity paradox after PCI in Asian populations. The obesity paradox was evident in all-cause mortality, cardiac mortality, and noncardiac mortality.

心血管疾病(CVDs)是导致全球疾病和死亡的主要因素。体重指数(BMI)是心血管风险预后的一个公认因素。大量研究证明,经皮冠状动脉介入治疗(PCI)后存在肥胖悖论。然而,在亚洲人群中,BMI 与 PCI 术后结果之间的关系尚未得到广泛研究。本研究旨在通过调查 BMI 与 PCI 后临床后果之间的关系,填补目前的认识空白,尤其关注亚洲人。研究人员通过 PubMed、ScienceDirect 和 Cochrane Library 进行了系统性检索,以确定有关亚洲人 BMI 对 PCI 后临床结果影响的研究。数据分析使用了 R Studio 4.3.2 软件。在纳入的 5 个队列中,共有 182,110 名患者接受了 PCI 治疗。对受试者进行的荟萃分析表明,与体重健康的人相比,超重患者的全因死亡风险较低(几率比[OR] = 0.60,95% 置信区间[CI] [0.57, 0.63],P < 0.0001),而与体重健康的人相比,肥胖患者的全因死亡风险较低(OR = 0.65,95% 置信区间[CI] [0.41, 1.05],P = 0.006)。研究还发现,超重患者(OR = 0.60,95% CI [0.39,0.91],P = 0.02)的心脏死亡风险较低。此外,肥胖患者(OR = 0.41,95% CI [0.19,0.88],P = 0.02)的非心脏病死亡风险也较低。不过,研究发现,各组患者在主要不良心血管事件、心肌梗死和出血方面没有差异。这项荟萃分析支持亚洲人在接受 PCI 治疗后存在肥胖悖论。肥胖悖论在全因死亡率、心源性死亡率和非心源性死亡率方面都很明显。
{"title":"The obesity paradox exists in Asia: A systematic review and meta-analysis of body mass index effects on clinical outcomes following percutaneous coronary intervention in Asia.","authors":"Andrianto, Chabib Fachry Albab, Nandha Pratama Mahardika","doi":"10.4103/tcmj.tcmj_317_23","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_317_23","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) are major contributors to illness and death globally. Body mass index (BMI) is a well-established prognostic factor on cardiovascular risk outcome. Numerous investigations have provided evidence for the existence of the obesity paradox after percutaneous coronary intervention (PCI). However, the association between BMI and the results following PCI has not been extensively investigated in Asian populations. The research aims to fill the current void in understanding by investigating the association between BMI and clinical consequences following PCI, with a particular focus on Asian individuals. A systematic search was conducted through PubMed, ScienceDirect, and Cochrane Library to identify studies examining the effect of BMI on clinical outcome after PCI in Asia. R Studio 4.3.2 software was used to carry out the analysis of the data. A total of 182,110 patients who had gone through PCI were found in the 5 included cohorts. A meta-analysis conducted on the subjects revealed that patients who were overweight (odds ratio [OR] = 0.60, 95% confidence interval [CI] [0.57, 0.63], <i>P</i> < 0.0001) had a lower risk of all-cause mortality compared to individuals with a healthy weight and patients with obesity (OR = 0.65, 95% CI [0.41, 1.05], <i>P</i> = 0.006) had a lower risk of all-cause mortality than healthy weight individuals. The study also found that overweight patients (OR = 0.60, 95% CI [0.39, 0.91], <i>P</i> = 0.02) had a lower risk of cardiac mortality. In addition, obese patients (OR = 0.41, 95% CI [0.19, 0.88], <i>P</i> = 0.02) had a lower risk of noncardiac mortality. However, the study found that there were no differences in major adverse cardiovascular event, myocardial infarction, and bleeding between all patient groups. This meta-analysis supports the presence of an obesity paradox after PCI in Asian populations. The obesity paradox was evident in all-cause mortality, cardiac mortality, and noncardiac mortality.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 4","pages":"387-395"},"PeriodicalIF":1.4,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nocturia, nocturnal polyuria, and nocturnal enuresis in adults: What we know and what we do not know. 成人夜尿症、夜间多尿症和夜间遗尿症:我们知道什么,我们不知道什么。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-27 eCollection Date: 2024-10-01 DOI: 10.4103/tcmj.tcmj_53_24
Tien-Lin Chang, Hann-Chorng Kuo

Nocturia is defined as the nocturnal frequency of one or more voiding episodes per night. It increases with aging and has an impact on sleep quality and the risks of falling and mortality. Nocturia disorder involves nighttime frequency, nocturnal polyuria, and nocturnal enuresis. In older adults with nocturia disorder, multiple factors could contribute to nocturia severity and characteristics, including poor sleep quality, lower urinary tract dysfunction, and excessive fluid output. Several nonurological medical diseases have been found to result in nocturia, such as hypertension, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, metabolic syndrome, and diabetes. Urological and medical assessments should be performed to diagnose nocturia disorder. A frequency volume chart to evaluate the nocturnal polyuria index, functional bladder capacity, and urodynamic study can reveal the presence of nocturnal polyuria and lower urinary tract dysfunction. Treatment should be based on multiple nocturia etiologies, and a combination of multiple therapies for individual pathophysiology will achieve a better treatment outcome.

夜尿是指每晚一次或多次的夜间排尿频率。它随着年龄的增长而增加,对睡眠质量、跌倒风险和死亡率都有影响。夜尿症包括夜间尿频、夜间多尿和夜间遗尿。在患有夜尿症的老年人中,多种因素可能会导致夜尿症的严重程度和特征,包括睡眠质量差、下尿路功能障碍和液体排出过多。已发现一些非泌尿系统疾病会导致夜尿,如高血压、充血性心力衰竭、慢性肾病、慢性阻塞性肺病、代谢综合征和糖尿病。诊断夜尿症应进行泌尿科和内科评估。通过尿频尿量图评估夜间多尿指数、功能性膀胱容量和尿动力学检查,可以发现是否存在夜间多尿和下尿路功能障碍。治疗应基于多种夜尿病因,针对不同的病理生理学采用多种疗法联合治疗,将取得更好的治疗效果。
{"title":"Nocturia, nocturnal polyuria, and nocturnal enuresis in adults: What we know and what we do not know.","authors":"Tien-Lin Chang, Hann-Chorng Kuo","doi":"10.4103/tcmj.tcmj_53_24","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_53_24","url":null,"abstract":"<p><p>Nocturia is defined as the nocturnal frequency of one or more voiding episodes per night. It increases with aging and has an impact on sleep quality and the risks of falling and mortality. Nocturia disorder involves nighttime frequency, nocturnal polyuria, and nocturnal enuresis. In older adults with nocturia disorder, multiple factors could contribute to nocturia severity and characteristics, including poor sleep quality, lower urinary tract dysfunction, and excessive fluid output. Several nonurological medical diseases have been found to result in nocturia, such as hypertension, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease, metabolic syndrome, and diabetes. Urological and medical assessments should be performed to diagnose nocturia disorder. A frequency volume chart to evaluate the nocturnal polyuria index, functional bladder capacity, and urodynamic study can reveal the presence of nocturnal polyuria and lower urinary tract dysfunction. Treatment should be based on multiple nocturia etiologies, and a combination of multiple therapies for individual pathophysiology will achieve a better treatment outcome.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 4","pages":"370-376"},"PeriodicalIF":1.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Do urinary tract infections affect the rate of periprosthetic joint infections in patients who underwent arthroplasty surgery? A systematic review and meta-analysis. 尿路感染会影响接受关节置换手术患者的假体周围关节感染率吗?系统回顾和荟萃分析。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-27 eCollection Date: 2024-07-01 DOI: 10.4103/tcmj.tcmj_309_23
Antoninus Hengky, Malvin Tandry, Kevin Gracia Pratama, Pauliana Pauliana, Christopher Kusumajaya, Astrawinata Guatama

Periprosthetic joint infection (PJI) is a significant issue in orthopedic surgery. Urinary tract infections (UTIs) and asymptomatic bacteriuria (ASB) have been identified as potential causes of PJI; however, evidence is inconclusive. Understanding these relationships is critical for improving therapy and patient outcomes. A systematic review was performed by conducting searches from PubMed, EBSCO, ProQuest, and manual searching with adherence to the Preferred Reporting Items for Systematic Review and Meta-Analysis 2020 guideline. Studies that reported UTI/ASB and PJI were included. Meta-analysis was conducted using a random-effects model using RevMan 5.4 software. A total of 14 studies were included with UTIs and ASB showed an overall association with increased risk of PJI (odds ratio [OR]: 1.84, 95% confidence interval [CI]: 1.14-2.99, P = 0.01). However, subgroup analysis for UTIs and ASB was not significant. Further analysis of UTIs in total hip arthroplasty (THA) surgery showed a significant association (OR: 1.76, 95% CI: 1.57-1.96) with PJI. Preoperative UTIs timing between 0 and 2 weeks before surgery showed an increased risk of PJI (OR: 1.45, 95% CI: 1.35-1.55). Antibiotic treatment in ASB did not significantly impact PJI rates. Urine and PJI sample cultures in four studies showed no correlation of microorganisms between the two sites. According to recent evidence, a statistically significant association was found between UTIs and PJI in patients who underwent THA surgery. However, ASB did not yield significant results in relation to PJI. These results should be supported by larger and well-designed studies to make proper clinical suggestion in future. For further research, it is recommended to adopt standardized criteria for outcome measurement and to involve larger sample sizes to enhance the reliability and generalizability of findings.

假体周围关节感染(PJI)是骨科手术中的一个重要问题。尿路感染(UTI)和无症状菌尿(ASB)已被确定为导致假体周围关节感染的潜在原因;但目前尚无定论。了解这些关系对于改善治疗和患者预后至关重要。通过在 PubMed、EBSCO、ProQuest 等网站上进行检索,并遵照《2020 年系统性综述和荟萃分析首选报告项目》指南进行人工检索,我们完成了一项系统性综述。纳入了报告UTI/ASB和PJI的研究。使用 RevMan 5.4 软件的随机效应模型进行 Meta 分析。共纳入了 14 项研究,UTI 和 ASB 显示与 PJI 风险增加有整体关联(几率比 [OR]:1.84,95% 置信区间 [CI]:1.14-2.99,P = 0.01)。然而,UTI 和 ASB 的亚组分析结果并不显著。对全髋关节置换术(THA)手术中UTI的进一步分析表明,UTI与PJI有显著关联(OR:1.76,95% CI:1.57-1.96)。术前 0 至 2 周内发生的尿毒症会增加 PJI 风险(OR:1.45,95% CI:1.35-1.55)。ASB中的抗生素治疗对PJI发生率没有明显影响。四项研究中的尿液和 PJI 样本培养显示,这两个部位的微生物没有相关性。最新证据显示,在接受 THA 手术的患者中,UTI 与 PJI 之间存在统计学意义上的显著关联。然而,ASB 与 PJI 的关系并不显著。这些结果应得到规模更大、设计更合理的研究的支持,以便在未来提出适当的临床建议。在进一步的研究中,建议采用标准化的结果测量标准,并采用更大的样本量,以提高研究结果的可靠性和可推广性。
{"title":"Do urinary tract infections affect the rate of periprosthetic joint infections in patients who underwent arthroplasty surgery? A systematic review and meta-analysis.","authors":"Antoninus Hengky, Malvin Tandry, Kevin Gracia Pratama, Pauliana Pauliana, Christopher Kusumajaya, Astrawinata Guatama","doi":"10.4103/tcmj.tcmj_309_23","DOIUrl":"10.4103/tcmj.tcmj_309_23","url":null,"abstract":"<p><p>Periprosthetic joint infection (PJI) is a significant issue in orthopedic surgery. Urinary tract infections (UTIs) and asymptomatic bacteriuria (ASB) have been identified as potential causes of PJI; however, evidence is inconclusive. Understanding these relationships is critical for improving therapy and patient outcomes. A systematic review was performed by conducting searches from PubMed, EBSCO, ProQuest, and manual searching with adherence to the Preferred Reporting Items for Systematic Review and Meta-Analysis 2020 guideline. Studies that reported UTI/ASB and PJI were included. Meta-analysis was conducted using a random-effects model using RevMan 5.4 software. A total of 14 studies were included with UTIs and ASB showed an overall association with increased risk of PJI (odds ratio [OR]: 1.84, 95% confidence interval [CI]: 1.14-2.99, <i>P</i> = 0.01). However, subgroup analysis for UTIs and ASB was not significant. Further analysis of UTIs in total hip arthroplasty (THA) surgery showed a significant association (OR: 1.76, 95% CI: 1.57-1.96) with PJI. Preoperative UTIs timing between 0 and 2 weeks before surgery showed an increased risk of PJI (OR: 1.45, 95% CI: 1.35-1.55). Antibiotic treatment in ASB did not significantly impact PJI rates. Urine and PJI sample cultures in four studies showed no correlation of microorganisms between the two sites. According to recent evidence, a statistically significant association was found between UTIs and PJI in patients who underwent THA surgery. However, ASB did not yield significant results in relation to PJI. These results should be supported by larger and well-designed studies to make proper clinical suggestion in future. For further research, it is recommended to adopt standardized criteria for outcome measurement and to involve larger sample sizes to enhance the reliability and generalizability of findings.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"275-283"},"PeriodicalIF":1.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
C-X-C motif chemokine ligand 12-C-X-C chemokine receptor type 4 signaling axis in cancer and the development of chemotherapeutic molecules. 癌症中的 C-X-C motif 趋化因子配体 12-C-X-C 趋化因子受体 4 型信号轴与化疗分子的开发。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-27 eCollection Date: 2024-07-01 DOI: 10.4103/tcmj.tcmj_52_24
Jui-Hung Yen, Chun-Chun Chang, Hao-Jen Hsu, Chin-Hao Yang, Hemalatha Mani, Je-Wen Liou

Chemokines are small, secreted cytokines crucial in the regulation of a variety of cell functions. The binding of chemokine C-X-C motif chemokine ligand 12 (CXCL12) (stromal cell-derived factor 1) to a G-protein-coupled receptor C-X-C chemokine receptor type 4 (CXCR4) triggers downstream signaling pathways with effects on cell survival, proliferation, chemotaxis, migration, and gene expression. Intensive and extensive investigations have provided evidence suggesting that the CXCL12-CXCR4 axis plays a pivotal role in tumor development, survival, angiogenesis, metastasis, as well as in creating tumor microenvironment, thus implying that this axis is a potential target for the development of cancer therapies. The structures of CXCL12 and CXCR4 have been resolved with experimental methods such as X-ray crystallography, NMR, or cryo-EM. Therefore, it is possible to apply structure-based computational approaches to discover, design, and modify therapeutic molecules for cancer treatments. Here, we summarize the current understanding of the roles played by the CXCL12-CXCR4 signaling axis in cellular functions linking to cancer progression and metastasis. This review also provides an introduction to protein structures of CXCL12 and CXCR4 and the application of computer simulation and analysis in understanding CXCR4 activation and antagonist binding. Furthermore, examples of strategies and current progress in CXCL12-CXCR4 axis-targeted development of therapeutic anticancer inhibitors are discussed.

趋化因子是一种小型分泌型细胞因子,对调节多种细胞功能至关重要。趋化因子 C-X-C 矩阵趋化因子配体 12(CXCL12)(基质细胞衍生因子 1)与 G 蛋白偶联受体 C-X-C 趋化因子受体 4 型(CXCR4)结合,触发下游信号通路,对细胞存活、增殖、趋化、迁移和基因表达产生影响。大量深入的研究表明,CXCL12-CXCR4 轴在肿瘤发生、存活、血管生成、转移以及肿瘤微环境的形成过程中起着关键作用,这意味着该轴是开发癌症疗法的潜在靶点。CXCL12 和 CXCR4 的结构已通过 X 射线晶体学、核磁共振或低温电子显微镜等实验方法得到解析。因此,应用基于结构的计算方法来发现、设计和改造用于癌症治疗的治疗分子成为可能。在此,我们总结了目前对 CXCL12-CXCR4 信号轴在与癌症进展和转移相关的细胞功能中所起作用的理解。本综述还介绍了 CXCL12 和 CXCR4 的蛋白质结构,以及计算机模拟和分析在理解 CXCR4 激活和拮抗剂结合方面的应用。此外,还讨论了针对 CXCL12-CXCR4 轴开发治疗性抗癌抑制剂的策略实例和当前进展。
{"title":"C-X-C motif chemokine ligand 12-C-X-C chemokine receptor type 4 signaling axis in cancer and the development of chemotherapeutic molecules.","authors":"Jui-Hung Yen, Chun-Chun Chang, Hao-Jen Hsu, Chin-Hao Yang, Hemalatha Mani, Je-Wen Liou","doi":"10.4103/tcmj.tcmj_52_24","DOIUrl":"10.4103/tcmj.tcmj_52_24","url":null,"abstract":"<p><p>Chemokines are small, secreted cytokines crucial in the regulation of a variety of cell functions. The binding of chemokine C-X-C motif chemokine ligand 12 (CXCL12) (stromal cell-derived factor 1) to a G-protein-coupled receptor C-X-C chemokine receptor type 4 (CXCR4) triggers downstream signaling pathways with effects on cell survival, proliferation, chemotaxis, migration, and gene expression. Intensive and extensive investigations have provided evidence suggesting that the CXCL12-CXCR4 axis plays a pivotal role in tumor development, survival, angiogenesis, metastasis, as well as in creating tumor microenvironment, thus implying that this axis is a potential target for the development of cancer therapies. The structures of CXCL12 and CXCR4 have been resolved with experimental methods such as X-ray crystallography, NMR, or cryo-EM. Therefore, it is possible to apply structure-based computational approaches to discover, design, and modify therapeutic molecules for cancer treatments. Here, we summarize the current understanding of the roles played by the CXCL12-CXCR4 signaling axis in cellular functions linking to cancer progression and metastasis. This review also provides an introduction to protein structures of CXCL12 and CXCR4 and the application of computer simulation and analysis in understanding CXCR4 activation and antagonist binding. Furthermore, examples of strategies and current progress in CXCL12-CXCR4 axis-targeted development of therapeutic anticancer inhibitors are discussed.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"231-239"},"PeriodicalIF":1.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracellular vesicles: Function, resilience, biomarker, bioengineering, and clinical implications. 细胞外囊泡:功能、复原力、生物标记、生物工程和临床意义。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-24 eCollection Date: 2024-07-01 DOI: 10.4103/tcmj.tcmj_28_24
Der-Shan Sun, Hsin-Hou Chang

Extracellular vesicles (EVs) have emerged as key players in intercellular communication, disease pathology, and therapeutic innovation. Initially overlooked as cellular debris, EVs are now recognized as vital mediators of cell-to-cell communication, ferrying a cargo of proteins, nucleic acids, and lipids, providing cellular resilience in response to stresses. This review provides a comprehensive overview of EVs, focusing on their role as biomarkers in disease diagnosis, their functional significance in physiological and pathological processes, and the potential of bioengineering for therapeutic applications. EVs offer a promising avenue for noninvasive disease diagnosis and monitoring, reflecting the physiological state of originating cells. Their diagnostic potential spans a spectrum of diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases. Moreover, their presence in bodily fluids such as blood, urine, and cerebrospinal fluid enhances their diagnostic utility, presenting advantages over traditional methods. Beyond diagnostics, EVs mediate crucial roles in intercellular communication, facilitating the transfer of bioactive molecules between cells. This communication modulates various physiological processes such as tissue regeneration, immune modulation, and neuronal communication. Dysregulation of EV-mediated communication is implicated in diseases such as cancer, immune disorders, and neurodegenerative diseases, highlighting their therapeutic potential. Bioengineering techniques offer avenues for manipulating EVs for therapeutic applications, from isolation and purification to engineering cargo and targeted delivery systems. These approaches hold promise for developing novel therapeutics tailored to specific diseases, revolutionizing personalized medicine. However, challenges such as standardization, scalability, and regulatory approval need addressing for successful clinical translation. Overall, EVs represent a dynamic frontier in biomedical research with vast potential for diagnostics, therapeutics, and personalized medicine.

细胞外囊泡(EVs)已成为细胞间通信、疾病病理和治疗创新的关键角色。细胞外囊泡最初被认为是细胞碎片,但现在人们认识到它是细胞间交流的重要媒介,能运送蛋白质、核酸和脂质等货物,提供细胞应对压力的复原力。这篇综述全面概述了EVs,重点是EVs在疾病诊断中作为生物标记物的作用、EVs在生理和病理过程中的功能意义以及生物工程在治疗应用中的潜力。EVs为无创疾病诊断和监测提供了一个前景广阔的途径,它反映了起源细胞的生理状态。它们的诊断潜力涵盖一系列疾病,包括癌症、心血管疾病、神经退行性疾病和传染病。此外,EVs 存在于血液、尿液和脑脊液等体液中,增强了其诊断效用,与传统方法相比更具优势。除诊断外,EVs 还在细胞间通信中发挥关键作用,促进生物活性分子在细胞间的转移。这种交流调节着各种生理过程,如组织再生、免疫调节和神经元交流。EV介导的通讯失调与癌症、免疫紊乱和神经退行性疾病等疾病有关,这凸显了它们的治疗潜力。生物工程技术提供了操纵 EVs 用于治疗的途径,从分离和纯化到工程货物和靶向递送系统。这些方法有望开发出针对特定疾病的新型疗法,从而彻底改变个性化医疗。然而,要成功实现临床转化,还需要解决标准化、可扩展性和监管审批等挑战。总之,EVs 代表了生物医学研究中一个充满活力的前沿领域,在诊断、治疗和个性化医疗方面具有巨大潜力。
{"title":"Extracellular vesicles: Function, resilience, biomarker, bioengineering, and clinical implications.","authors":"Der-Shan Sun, Hsin-Hou Chang","doi":"10.4103/tcmj.tcmj_28_24","DOIUrl":"10.4103/tcmj.tcmj_28_24","url":null,"abstract":"<p><p>Extracellular vesicles (EVs) have emerged as key players in intercellular communication, disease pathology, and therapeutic innovation. Initially overlooked as cellular debris, EVs are now recognized as vital mediators of cell-to-cell communication, ferrying a cargo of proteins, nucleic acids, and lipids, providing cellular resilience in response to stresses. This review provides a comprehensive overview of EVs, focusing on their role as biomarkers in disease diagnosis, their functional significance in physiological and pathological processes, and the potential of bioengineering for therapeutic applications. EVs offer a promising avenue for noninvasive disease diagnosis and monitoring, reflecting the physiological state of originating cells. Their diagnostic potential spans a spectrum of diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases. Moreover, their presence in bodily fluids such as blood, urine, and cerebrospinal fluid enhances their diagnostic utility, presenting advantages over traditional methods. Beyond diagnostics, EVs mediate crucial roles in intercellular communication, facilitating the transfer of bioactive molecules between cells. This communication modulates various physiological processes such as tissue regeneration, immune modulation, and neuronal communication. Dysregulation of EV-mediated communication is implicated in diseases such as cancer, immune disorders, and neurodegenerative diseases, highlighting their therapeutic potential. Bioengineering techniques offer avenues for manipulating EVs for therapeutic applications, from isolation and purification to engineering cargo and targeted delivery systems. These approaches hold promise for developing novel therapeutics tailored to specific diseases, revolutionizing personalized medicine. However, challenges such as standardization, scalability, and regulatory approval need addressing for successful clinical translation. Overall, EVs represent a dynamic frontier in biomedical research with vast potential for diagnostics, therapeutics, and personalized medicine.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"251-259"},"PeriodicalIF":1.4,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for reoperation after discectomy of lumbar herniated intervertebral disc disease. 腰椎间盘突出症椎间盘切除术后再次手术的风险因素。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-04-30 eCollection Date: 2024-07-01 DOI: 10.4103/tcmj.tcmj_206_23
Cheng-Huan Peng, Ing-Ho Chen, Tzai-Chiu Yu, Jen-Hung Wang, Wen-Tien Wu, Kuang-Ting Yeh

Objectives: Discectomy is the most common surgery for lumbar herniated intervertebral disc (HIVD) disease. However, 5%-24% of patients undergo a second surgery due to recurrent disc herniation.

Materials and methods: This study was aimed to identify the risk factors for reoperation after discectomy of lumbar HIVD and recommend treatment for patients with a high risk of reoperation. We recruited patients diagnosed as having single-level lumbar HIVD who underwent open discectomy from January 1, 2000, to December 31, 2012 in our hospital. We used a survival curve to inspect the survival time and reoperation rate after surgery. We discussed the correlation of reoperation rate with discectomy level, body mass index, heavy lifting after surgery, sex, and age. Furthermore, we investigated the correlation between the experience of a surgeon and the reoperation rate.

Results: A total of 619 patients were enrolled in our study. Most patients were 40-60 years old (48.8%), and most of them had herniation at L4/5 level (48.9%). The 8-year survival rate was 92%. Weight lifting after surgery may increase the reoperation rate by 115 and 18 times for those >60 years and <40 years, respectively. In addition, less experience of the surgeon and female sex had a high reoperation rate.

Conclusion: Postoperative working modification may be very important for preventing patients from recurrent HIVD. For elderly people with HIVD, a more conservative therapy could be selected. If patients with lumbar spine hypermobility or severe degeneration require wide laminectomy, primary fusion should be considered.

目的:椎间盘切除术是治疗腰椎间盘突出症(HIVD)最常见的手术。然而,5%-24%的患者会因复发性椎间盘突出症而接受第二次手术:本研究旨在确定腰椎间盘突出症(HIVD)椎间盘切除术后再次手术的风险因素,并对再次手术风险高的患者提出治疗建议。我们招募了 2000 年 1 月 1 日至 2012 年 12 月 31 日期间在我院接受开刀椎间盘切除术的单层腰椎 HIVD 患者。我们用生存曲线来检验术后生存时间和再手术率。我们讨论了再手术率与椎间盘切除水平、体重指数、术后重体力劳动、性别和年龄的相关性。此外,我们还研究了外科医生的经验与再手术率之间的相关性:共有 619 名患者参与了我们的研究。大多数患者的年龄在 40-60 岁之间(48.8%),大多数患者的腰椎疝位于 L4/5 水平(48.9%)。8年生存率为92%。术后举重可能会使再次手术率增加 115 倍,年龄大于 60 岁的患者可能会增加 18 倍:术后调整工作对于防止患者复发 HIVD 可能非常重要。对于患有 HIVD 的老年人,可以选择更为保守的疗法。如果腰椎活动度大或退变严重的患者需要进行宽椎板切除术,则应考虑进行初次融合术。
{"title":"Risk factors for reoperation after discectomy of lumbar herniated intervertebral disc disease.","authors":"Cheng-Huan Peng, Ing-Ho Chen, Tzai-Chiu Yu, Jen-Hung Wang, Wen-Tien Wu, Kuang-Ting Yeh","doi":"10.4103/tcmj.tcmj_206_23","DOIUrl":"10.4103/tcmj.tcmj_206_23","url":null,"abstract":"<p><strong>Objectives: </strong>Discectomy is the most common surgery for lumbar herniated intervertebral disc (HIVD) disease. However, 5%-24% of patients undergo a second surgery due to recurrent disc herniation.</p><p><strong>Materials and methods: </strong>This study was aimed to identify the risk factors for reoperation after discectomy of lumbar HIVD and recommend treatment for patients with a high risk of reoperation. We recruited patients diagnosed as having single-level lumbar HIVD who underwent open discectomy from January 1, 2000, to December 31, 2012 in our hospital. We used a survival curve to inspect the survival time and reoperation rate after surgery. We discussed the correlation of reoperation rate with discectomy level, body mass index, heavy lifting after surgery, sex, and age. Furthermore, we investigated the correlation between the experience of a surgeon and the reoperation rate.</p><p><strong>Results: </strong>A total of 619 patients were enrolled in our study. Most patients were 40-60 years old (48.8%), and most of them had herniation at L4/5 level (48.9%). The 8-year survival rate was 92%. Weight lifting after surgery may increase the reoperation rate by 115 and 18 times for those >60 years and <40 years, respectively. In addition, less experience of the surgeon and female sex had a high reoperation rate.</p><p><strong>Conclusion: </strong>Postoperative working modification may be very important for preventing patients from recurrent HIVD. For elderly people with HIVD, a more conservative therapy could be selected. If patients with lumbar spine hypermobility or severe degeneration require wide laminectomy, primary fusion should be considered.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"298-303"},"PeriodicalIF":1.4,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The level of discomfort during the use of different circuits of the mechanical ventilator. 使用机械呼吸机不同回路时的不适程度。
IF 1.4 Q2 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-04-30 eCollection Date: 2024-07-01 DOI: 10.4103/tcmj.tcmj_236_23
Meng-Yi Liu, Pei-Shan Hsu, Chiu-Feng Wu, Yao-Kuang Wu, Mei-Chen Yang, Wen-Lin Su, I-Shiang Tzeng, Chou-Chin Lan

Objectives: Endotracheal tube (ETT) intubation is a life-saving procedure in patients with respiratory failure. However, the presence of an ETT can cause significant discomfort. A tracheostomy tube is used to administer a mechanical ventilator, resulting in a more stable airway and fewer serious injuries. Noninvasive ventilators (NIPPVs) administer ventilation through masks and must be tightly fixed to the face. ETT, tracheostomy, and NIPPV are the most common methods of ventilator maintenance. However, these interventions often cause discomfort to patients. This study aimed to compare discomfort associated with ETT, tracheostomy, and NIPPV.

Materials and methods: Forty-nine conscious patients with postextubation NIPPV and eight conscious patients who underwent postextubation tracheotomy were evaluated for discomfort. A questionnaire survey on discomfort was performed before and after NIPPV or tracheostomy. These patients reported their level of discomfort on a visual analog scale.

Results: The levels of sore throat, nasal pain, body pain, activity limitation, respiratory discomfort, oral discomfort, difficulty coughing sputum, worry about respiratory tube disconnection, back pain, anxiety, worry about long-term admission, sleep disturbance, and general discomfort during ETT intubation were higher than during tracheostomy or NIPPV (all P < 0.05). The mean level of discomfort was approximately 5-6 points (moderate) in patients with ETT and 2-3 points (mild) in patients with NIPPV or tracheostomy.

Conclusion: The level of discomfort was higher in patients who underwent ETT intubation than in those who underwent NIPPV or tracheostomy. However, the level of discomfort was similar between the patients with NIPPV and those who underwent tracheostomy.

目的:气管内插管(ETT)是呼吸衰竭患者的一项救生程序。然而,气管内插管会给患者带来明显不适。气管插管用于使用机械呼吸机,可使气道更加稳定,减少严重损伤。无创呼吸机(NIPPV)通过面罩进行通气,必须紧紧固定在面部。ETT、气管切开术和 NIPPV 是最常见的呼吸机维护方法。然而,这些干预措施往往会给患者带来不适。本研究旨在比较与 ETT、气管切开术和 NIPPV 相关的不适感:对 49 名接受拔管后 NIPPV 的神志清醒患者和 8 名接受拔管后气管切开术的神志清醒患者进行了不适感评估。在 NIPPV 或气管切开术前后进行了不适感问卷调查。这些患者用视觉模拟量表报告了他们的不适程度:结果:在 ETT 插管期间,患者的咽喉疼痛、鼻腔疼痛、身体疼痛、活动受限、呼吸道不适、口腔不适、咳痰困难、担心呼吸管断开、背部疼痛、焦虑、担心长期入院、睡眠障碍和全身不适程度均高于气管切开术或 NIPPV 期间(所有 P <0.05)。ETT患者的平均不适程度约为5-6分(中度),NIPPV或气管切开患者的平均不适程度约为2-3分(轻度):结论:接受 ETT 插管的患者的不适程度高于接受 NIPPV 或气管切开术的患者。不过,NIPPV 患者和气管切开术患者的不适程度相似。
{"title":"The level of discomfort during the use of different circuits of the mechanical ventilator.","authors":"Meng-Yi Liu, Pei-Shan Hsu, Chiu-Feng Wu, Yao-Kuang Wu, Mei-Chen Yang, Wen-Lin Su, I-Shiang Tzeng, Chou-Chin Lan","doi":"10.4103/tcmj.tcmj_236_23","DOIUrl":"10.4103/tcmj.tcmj_236_23","url":null,"abstract":"<p><strong>Objectives: </strong>Endotracheal tube (ETT) intubation is a life-saving procedure in patients with respiratory failure. However, the presence of an ETT can cause significant discomfort. A tracheostomy tube is used to administer a mechanical ventilator, resulting in a more stable airway and fewer serious injuries. Noninvasive ventilators (NIPPVs) administer ventilation through masks and must be tightly fixed to the face. ETT, tracheostomy, and NIPPV are the most common methods of ventilator maintenance. However, these interventions often cause discomfort to patients. This study aimed to compare discomfort associated with ETT, tracheostomy, and NIPPV.</p><p><strong>Materials and methods: </strong>Forty-nine conscious patients with postextubation NIPPV and eight conscious patients who underwent postextubation tracheotomy were evaluated for discomfort. A questionnaire survey on discomfort was performed before and after NIPPV or tracheostomy. These patients reported their level of discomfort on a visual analog scale.</p><p><strong>Results: </strong>The levels of sore throat, nasal pain, body pain, activity limitation, respiratory discomfort, oral discomfort, difficulty coughing sputum, worry about respiratory tube disconnection, back pain, anxiety, worry about long-term admission, sleep disturbance, and general discomfort during ETT intubation were higher than during tracheostomy or NIPPV (all <i>P</i> < 0.05). The mean level of discomfort was approximately 5-6 points (moderate) in patients with ETT and 2-3 points (mild) in patients with NIPPV or tracheostomy.</p><p><strong>Conclusion: </strong>The level of discomfort was higher in patients who underwent ETT intubation than in those who underwent NIPPV or tracheostomy. However, the level of discomfort was similar between the patients with NIPPV and those who underwent tracheostomy.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"311-318"},"PeriodicalIF":1.4,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Tzu Chi Medical Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1